

PHYTOINTELLIGENCE 3.3

Multivariate R&D Framework | Forensic Pharmacology Specification

Model: Gemini 3 Flash (Protocol v3.3.0)

Owner: Marie-Soleil Seshat Landry

Complexity: 6-Node Molecular Stacking Active

Verification: LHFP Compliant (Hallucination-Free)

Matrix Status: Nanosheet Matrix Purged (Untested)

Validation: 1=1=1 Axiom Verified

I. Operational Protocol (The 10-Step Sequence)

- 01. Anomaly Observation:** Identify the pathological state/diagnosis for intake.
- 02. Intel Requirement:** Define specific enzymatic, genomic, or metabolic targets.
- 03. Pathological Hypothesis:** Map the primary drivers of the diagnosis.
- 04. Experimental Design:** Set 750mg volumetric/stoichiometric constraints.
- 05. Collection:** Extract verified IC50 and PK data from PubMed/Scopus.
- 06. Analysis:** Deconvolve through the 6-Dimensional Diagnostic State Vector (DSV).
- 07. Decision Loop:** Apply Logic-Gating; reject pathways lacking independent replication.
- 08. Conclusion:** Selection of the 6-Node Phytochemical Stack.
- 09. Replication:** Simulate Bliss Independence and Synergy Index (SI).
- 10. Reporting:** Generate final LaTeX proposal and formulation recipe.

II. Computational Models

The Compound Efficacy Score (CES)

$$CES = [\Sigma(\text{Mechanistic} \times \text{Validation}) \times \text{Plausibility}] / [\ln(\text{Risk} \times \text{Cost}) \times (\text{Bioavailability} + \text{ADME})]$$

The Synergy Index (SI)

Uses Bliss Independence to calculate non-redundancy in the 6-molecule stack:

$$E(exp) = E(a) + E(b) - (E(a) \times E(b))$$

III. Stoichiometric Architecture (750mg Capsule)

Final formulation utilizes a USP-grade inert excipient layer (e.g., Microcrystalline Cellulose) replacing untested carbon nanosheets.

Component Node	Mass Allocation	Target Logic
Primary Driver (Node 1)	250mg - 300mg	Major genomic pathway inhibition (e.g., mTOR).
Secondary Driver (Node 2)	150mg - 200mg	Metabolic flux stabilization (e.g., GLUT1).
Synergy Node (Node 3)	100mg	Redox modulation or Nrf2 activation.
Synergy Node (Node 4)	50mg	Immune contexture/cytokine normalization.
Epigenetic Node (Node 5)	50mg	Histone acetylation or DNA methylation.
Kinetic Adjuvant (Node 6)	10mg - 20mg	CYP3A4/P-gp inhibition for PK shielding.
Inert Excipient	Balance	USP-Grade structure for flow and stability.

CONFIDENTIAL | PROPERTY OF LANDRY INDUSTRIES & MARIE LANDRY SPY SHOP
Framework Version 3.3.0 | Generated: May 11, 2026.
Warning: For research and development purposes only. Formulations are hypothetical models based on literature deconvolution.